Published in AIDS Weekly, August 11th, 1997
GEM91 is a first generation (phosphorothioate) antisense oligonucleotide which targets the gag site in the HIV genome. In the Phase II trial, three of the nine subjects tested experienced decreases in platelet counts that required dose interruption. Additionally, a review of the data showed inconsistent responses to the treatment and failed to confirm the decrease in cellular viremia observed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.